Uncategorized Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health by Mbio2018|Published September 1, 2018 https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Published June 1, 2018 Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University
Published April 8, 2025 Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 Inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation
Published May 8, 2025 Manhattan BioSolutions’ TxD ADC Collaboration Secures REACH Award from the New York Center for Biotechnology at the Stony Brook University
Published January 30, 2025 Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers
